<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363035</url>
  </required_header>
  <id_info>
    <org_study_id>H-REPLACE-201711</org_study_id>
    <nct_id>NCT03363035</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome</brief_title>
  <acronym>H-REPLACE</acronym>
  <official_title>Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      H-REPLACE trial is a prospective, randomized, open-label, active-controlled, multicenter
      study in participants with ACS (STEMI or NSTEMI, unstable angina). All eligible participants
      receiving background treatment of aspirin plus clopidogrel or ticagrelor will be randomly
      assigned to either oral rivaroxaban 2.5 mg twice daily or rivaroxaban 5 mg twice daily or
      subcutaneous (SC) enoxaparin 1mg/kg twice daily until hospital discharge or 12 hours before
      revascularization therapy for a maximum of 8 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute coronary syndrome (ACS) is a serious and life threatening condition. Anticoagulation
      during the acute phase of ACS is effective in reducing ischaemic events. The combination
      regimen of anticoagulation with dual antiplatelet therapy (DAPT) strategy is more effective
      than either treatment alone. The most widely used parenteral anticoagulation agent in ACS
      patients is enoxaparin (1 mg/kg administered subcutaneously twice daily).

      Rivaroxaban is a novel oral anticoagulant with potent anti-Xa activity, which might be an
      attractive alternative drug to enoxaparin. In fact, rivaroxaban was consistently shown to be
      non-inferior to enoxaparin therapy aimed to reduce the event of recurrent venous
      thromboembolism. Moreover, the bleeding risk of low dose of rivaroxaban is low and acceptable
      (1.0-2.5%) during the acute phase of ACS as shown by ATLAS ACS-TIMI 46 Trial, and the
      bleeding risk of enoxaparin during the acute phase of ACS was 4.3% as shown in a
      meta-analysis.

      We thus hypothesized that the safety and efficacy of rivaroxaban during the acute phase of
      ACS is non-inferior to enoxaparin and designed this prospective, randomized, open-label,
      active-controlled, multicenter study in participants with ACS (STEMI or NSTEMI or unstable
      angina). All eligible participants receiving background treatment of aspirin plus clopidogrel
      or ticagrelor will be randomly assigned to either receive oral rivaroxaban 2.5 mg twice daily
      or oral rivaroxaban 5 mg twice daily or enoxaparin 1mg/kg twice daily SC until hospital
      discharge or 12 hours before revascularization therapy for a maximum of 8 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Outcome: The percentage of patients with minor, clinically relevant non-major (CRNM) and major bleeding [International Society on Thrombosis and Haemostasis (ISTH) definition of bleeding]</measure>
    <time_frame>From the time of randomization (Day 1) up to completion of the follow up phase (Month 6)</time_frame>
    <description>The percentage of patients with the first occurrence of bleeding event according to ISTH definition. The statistical analysis was based on the occurrence of the bleeding event from randomization to Month 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Outcome: The percentage of patients with the composite endpoint of cardiac death, myocardial infarction, re-revascularization or stroke.</measure>
    <time_frame>From the time of randomization (Day 1) up to completion of the follow up phase (Month 6).</time_frame>
    <description>The percentage of patients with the first occurrence of the composite of death, myocardial infarction, re-revascularization or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event up to Month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with the cardiac-related rehospitalization.</measure>
    <time_frame>From the time of randomization (Day 1) up to completion of the follow up phase (Month 6).</time_frame>
    <description>The percentage of patients with the cardiac-related rehospitalization. The statistical analysis was based on the time from randomization to the first occurrence of the event up to Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with the all-cause death.</measure>
    <time_frame>From the time of randomization (Day 1) up to completion of the follow up phase (Month 6).</time_frame>
    <description>The percentage of patients with the all-cause death. The statistical analysis was based on the time from randomization to the first occurrence of the event up to Month 6.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3390</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 2.5 mg rivaroxaban tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 5 mg rivaroxaban tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin 1mg/kg twice daily SC twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 2.5 mg</intervention_name>
    <description>One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.</description>
    <arm_group_label>Rivaroxaban 2.5 mg</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 5 mg</intervention_name>
    <description>One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.</description>
    <arm_group_label>Rivaroxaban 5 mg</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.</description>
    <arm_group_label>enoxaparin</arm_group_label>
    <other_name>LWMH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥ 18 years

          -  Diagnosed with ACS (STEMI, NSTEMI, unstable angina)

          -  With an indication for short-term combination use of DAPT and enoxaparin.

        Exclusion Criteria:

          -  Already received thrombolytic therapy or revascularization or needing
             revascularization therapy in 12 hours.

          -  With platelet glycoprotein IIb/IIIa receptor antagonist therapy.

          -  With increased bleeding risk, such as but not limited to, active internal bleeding,
             clinically significant bleeding, bleeding at a non-compressible site, or bleeding
             diathesis within 30 days of randomization; platelet count less than 90,000/μL at
             screening; intracranial hemorrhage; major surgery, biopsy of a parenchymal organ, or
             serious trauma within 30 days before randomization; clinically significant
             gastrointestinal bleeding within 12 months before randomization; an international
             normalized ratio known to be＞1.5 at the time of screening; abciximab bolus or infusion
             within the preceding 8 hours, or an eptifibatide or tirofiban bolus or infusion within
             the past 2 hours preceding randomization; or any other condition known to increase the
             risk of bleeding.

          -  Severe concomitant condition or disease, such as cardiogenic shock at the time of
             randomization, ventricular arrhythmia refractory to treatment at the time of
             randomization, calculated creatinine clearance b 30 mL/min at screening, known
             significant liver disease (e.g., acute hepatitis, chronic active hepatitis,
             cirrhosis), or liver function test abnormalities (confirmed with repeat testing) which
             would require study drug discontinuation, i.e., aminoleucine transferase (ALT) ＞5 ×
             the upper limit of the normal range (ULN) or ALT ＞3 × ULN plus total bilirubin ＞2 ×
             ULN, prior ischemic stroke or transient ischemia attack, anemia (i.e., hemoglobin ＜ 10
             g/ dL＝ at screening, known clinical history of human immunodeficiency virus infection
             at screening, substance abuse (drug or alcohol) problem within the previous 6 months
             or any severe condition such as cancer that would limit life expectancy to less than 6
             months.

          -  With an indication for long-term oral anticoagulation therapy such as atrial
             fibrillation, venous thromboembolism, or prior placement of a mechanical heart valve.

          -  With other contraindications for use of rivaroxaban and enoxaparin.

          -  Enrolled in another clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenghua Zhou, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenghua Zhou, Ph.D.</last_name>
    <phone>+86 0731-85292013</phone>
    <email>zhoushenghua@csu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First People's Hospital of Changde City</name>
      <address>
        <city>Changde</city>
        <state>Hunan</state>
        <zip>415003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangqing Ge, Ph.D.</last_name>
      <phone>+86 13973652828</phone>
      <email>geliangqing@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changsha Central Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luping Jiang, Ph.D.</last_name>
      <phone>+86 18374892303</phone>
      <email>lukejlp@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhaofen Zheng, Ph.D.</last_name>
      <phone>+86 13974829586</phone>
      <email>zhaofenz@foxmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Forth Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao Gong, M.D.</last_name>
      <phone>+86 13873182948</phone>
      <email>949527198@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Hunan University of Chinese Medicine</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yizhi Wu, M.D.</last_name>
      <phone>+86 18008485122</phone>
      <email>yywyz@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shenghua Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guang Fu, M.D.</last_name>
      <phone>+86 13755170528</phone>
      <email>fuguangyisheng@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihong Jiang, Ph.D.</last_name>
      <phone>+86 13786113632</phone>
      <email>jwhxy3@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yumin Zhang, M.D.</last_name>
      <phone>+86 13574145995</phone>
      <email>20428251@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Hunan Province</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>430100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiang Liu, M.D.</last_name>
      <phone>+86 13975198853</phone>
      <email>liuxiang_0927@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Chenzhou</name>
      <address>
        <city>Chenzhou</city>
        <state>Hunan</state>
        <zip>423000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhonghua Wang, M.D.</last_name>
      <phone>+86 13975521597</phone>
      <email>105025@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changhui Liu, Ph.D.</last_name>
      <phone>+86 13786435885</phone>
      <email>liuchanghuidaoshi@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of University of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaofeng Zeng, Ph.D.</last_name>
      <phone>+86 13873418573</phone>
      <email>2379795177@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Hunan University of Medicine</name>
      <address>
        <city>Huaihua</city>
        <state>Hunan</state>
        <zip>418000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youliang Huang, M.D.</last_name>
      <phone>+86 13974501620</phone>
      <email>1469477867@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Huaihua</name>
      <address>
        <city>Huaihua</city>
        <state>Hunan</state>
        <zip>418000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Shen, M.D.</last_name>
      <phone>+86 13974531980</phone>
      <email>337825375@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jishou University</name>
      <address>
        <city>Jishou</city>
        <state>Hunan</state>
        <zip>416000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Can Zhu, M.D.</last_name>
      <phone>+86 13907439435</phone>
      <email>zc0629@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Loudi</name>
      <address>
        <city>Loudi</city>
        <state>Hunan</state>
        <zip>417000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huaqing Tan, M.D.</last_name>
      <phone>+86 13607389129</phone>
      <email>1063543926@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Shaoyang</name>
      <address>
        <city>Shaoyang</city>
        <state>Hunan</state>
        <zip>422000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zewei Ouyang, M.D.</last_name>
      <phone>+86 13337391467</phone>
      <email>zwycy4137@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangtan Central Hospital</name>
      <address>
        <city>Xiangtan</city>
        <state>Hunan</state>
        <zip>411413</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, M.D.</last_name>
      <phone>+86 13607327390</phone>
      <email>hh13607327390@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangxiang People's Hospital</name>
      <address>
        <city>Xianxiang</city>
        <state>Hunan</state>
        <zip>411400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chonglun Zhou, M.D.</last_name>
      <phone>+86 13975236189</phone>
      <email>897236609@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yiyang Central Hospital</name>
      <address>
        <city>Yiyang</city>
        <state>Hunan</state>
        <zip>413000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianming Wu, M.D.</last_name>
      <phone>+86 13973741819</phone>
      <email>13973741819@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Yueyang</name>
      <address>
        <city>Yueyang</city>
        <state>Hunan</state>
        <zip>414000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiping Xu, M.D.</last_name>
      <phone>+86 13807302918</phone>
      <email>xxps@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhuzhou Central Hospital</name>
      <address>
        <city>Zhuzhou</city>
        <state>Hunan</state>
        <zip>412007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fan Ouyang, Ph.D.</last_name>
      <phone>+86 13307327791</phone>
      <email>1641261977@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Shenghua Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

